Sangamo Therapeutics (SGMO), a clinical-stage biotechnology company focused on genomic medicines, demonstrates compliant debt and liquidity ratios but fails due to an interest income ratio of 10.14% exceeding the 5% threshold across standards. Business activities in gene therapy are permissible under Shariah principles. The company is not included in any major Shariah indices, leading to an overall non-compliant status. Purification of 10.14% of dividends is required. Investors should monitor financial improvements and consult scholars for personalized rulings.